Completed NA INTERVENTIONAL 1-arm NCT03526471

Omega™ Left Atrial Appendage (LAA) Occluder in Patients With Non-Valvular Atrial Fibrillation

Prospective, Single-arm Study to Assess the Safety and Performance of the Omega™ Left Atrial Appendage (LAA) Occluder in Patients With Non-Valvular Atrial Fibrillation and High Bleeding Risk

Sponsor: MedPass International

Conditions Atrial Fibrillation

Interventions Omega™ Left Atrial Appendage (LAA) Occluder

Updated 6 times since 2018 Last updated: Aug 25, 2020 Started: Jun 1, 2019 Primary completion: Jan 30, 2020 Completion: Mar 31, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A NA clinical study on Atrial Fibrillation, this trial is completed. The trial is conducted by MedPass International and has accumulated 6 data snapshots since 2019. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Sep 2020 — Jan 2021 [monthly]

Completed NA

Status: Not Yet Recruiting → Completed
May 2019 — Sep 2020 [monthly]

Not Yet Recruiting NA

▶ Show 1 earlier version

Jun 2018 — May 2019 [monthly]

Not Yet Recruiting NA

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

MedPass International
Vascular Innovations Co. Ltd.

Data source: Vascular Innovations Co. Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Copenhagen, Denmark
• Pathum Wan, Thailand